On December 27, 2018, Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical"), a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharmaceutical"), became the first anti-tuberculosis first-line drug pyrazinamide tablet The home passed the consistency evaluation. Pyrazinamide tablets are anti-tuberculosis drugs and can be combined with other anti-tuberculosis drugs (such as isoniazid, rifampicin and ethambutol) for the treatment of tuberculosis.

As a subsidiary of Fosun Pharma, Hongqi Pharmaceuticals always regards independent innovation as the driving force for corporate development, and continues to improve the drug R&D and innovation system of “combination of imitation and innovation”. As of November 2018, R&D expenses of approximately RMB 9.3 million (unaudited) have been invested in the evaluation of the consistency of pyrazinamide tablets.

The smooth passing of the consistency evaluation shows that the pyrazinamide tablets of Hongqi Pharmaceutical have reached the same quality and efficacy as the original drugs. Drug consistency evaluation, that is, drug consistency research, is a high standard requirement for generic drugs and original research drugs to "manage consistency, intermediate process consistency, and quality standard consistency throughout the process". Hongqi Pharmaceutical has been conducting research on drug consistency in strict accordance with national requirements to improve the safety and effectiveness of drugs, to ensure the safety and effectiveness of drugs used by the people, and to help the country achieve the goal of ending tuberculosis by 2035 as soon as possible.